Compare Gilead Sciences, Inc. (GILD) vs Mondaycom Ltd (MNDY) Price & Performance

Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.

Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.

Monday.com (MNDY) trades at $84.4, down 4.76% amid mixed signals. The stock shows strong fundamentals with Q2 2026 EPS of $1.48 beating estimates by 33%, revenue growth of 22% year-over-year, and a high gross margin of 88.74%. However, weak Q3 revenue guidance has triggered a sell-off. Technical indicators are neutral with support at $83 and resistance at $89. Analyst consensus remains bullish with a $113.38 price target, but near-term volatility persists due to growth concerns.

The outlook is cautiously optimistic given solid earnings beats and AI product traction, but investor sentiment is tempered by slowing revenue guidance. Key risks include SaaS sector pressures and execution challenges in shifting to enterprise AI. Upside potential exists if the company exceeds Q3 expectations, though volatility may continue until growth reaccelerates.